Use of prescription drug samples in the US and implications for pharmacoepidemiologic research: a systematic search of the literature

References

• Schwartz LM, Woloshin S. Medical Marketing in the United States, 1997-2016. JAMA. 2019;321:80–96.
   PubMed Web of Science ®Google Scholar
• King AC, Schwartz LM, Woloshin S, et al. Survey of the frequency of drug company detailing visits and free sample closets in practices delivering primary care. JAMA Intern Med. 2020. DOI:10.1001/jamainternmed.2019:6770.
   Web of Science ®Google Scholar
• Tran LL. Drug samples: why not? Virtual Mentor. 2014;16:245–251.
   PubMedGoogle Scholar
• Murshid MA, Mohaidin Z. A systematic review of the influence of medical representatives and promotional tools on prescribing: a comparison between developed and developing countries. Int J Pharm Healthcare Marketing. 2017;11:361–394.
   Web of Science ®Google Scholar
• Chimonas S, Kassirer JP. No More Free Drug Samples? PLoS Med. 2009;6.
   PubMed Web of Science ®Google Scholar
• Guglielmo BJ. The Cost of pharmaceutical company detailing visits and medication samples. JAMA Intern Med. 2020.
   PubMed Web of Science ®Google Scholar
• Brown JD, Doshi PA, Talbert JC. Utilization of free medication samples in the United States in a nationally representative sample: 2009–2013. Res Social Adm Pharm. 2017;13:193–200.
   PubMed Web of Science ®Google Scholar
• Hampp C, Greene P, Pinheiro SP. Use of prescription drug samples in the USA: a descriptive study with considerations for pharmacoepidemiology. Drug Saf. 2016;39:261–270.
   PubMed Web of Science ®Google Scholar
• Hurley MP, Stafford RS, Lane AT. Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea. JAMA Dermatology. 2014;150:487–493.
   PubMed Web of Science ®Google Scholar
• Tjia J, Briesacher BA, Soumerai SB, et al. Medicare beneficiaries and free prescription drug samples: a national survey. J Gen Intern Med. 2008;23:1727.
   Web of Science ®Google Scholar
• Cutrona SL, Woolhandler S, Lasser KE, et al. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98:284–289.
   PubMed Web of Science ®Google Scholar
• Cutrona SL, Woolhandler S, Lasser KE, et al. Free drug samples in the United States: characteristics of pediatric recipients and safety concerns. Pediatrics. 2008;122:736–742.
   PubMed Web of Science ®Google Scholar
• Electricwala B, Carroll N. Prevalence of Medication use not captured by prescription claims databases – an analysis using 2012 Medical Expenditure Panel Survey Data. Value Health. 2015;18:A84.
   PubMed Web of Science ®Google Scholar
• Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Med Care. 2008;46 394–402.
   PubMed Web of Science ®Google Scholar
• Strom BL. What Is Pharmacoepidemiology? Pharmacoepidemiology, 6th Ed. Hoboken, NJ: Wiley-Blackwell; 2020:1–26.
   Google Scholar
• Strom BL Overview of Electronic Databases in Pharmacoepidemiology. Pharmacoepidemiology, 6th Ed. Hoboken, NJ: Wiley-Blackwell; 2020:203–210.
   Google Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–337.
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC, Balasubramanian A, Farley JF, et al. Completeness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug Saf. 2013;22:899–906.
   PubMed Web of Science ®Google Scholar
• Funk MJ, Landi SN. Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. Curr Epidemiol Rep. 2014;1:175–185.
   PubMedGoogle Scholar
• Cepeda MS, Fife D, Denarié M, et al. Quantification of missing prescriptions in commercial claims databases: results of a cohort study. Pharmacoepidemiol Drug Saf. 2017;26:386–392.
   PubMed Web of Science ®Google Scholar
• Fischer MA. Knowing the Previously unknown: identification of a methodological challenge for pharmacoepidemiology. Med Care. 2014;52:767–769.
   PubMed Web of Science ®Google Scholar
• Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47:731–737.
   PubMed Web of Science ®Google Scholar
• CFR - Code of Federal Regulations Title 21 n.d. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=203.3 (2020 Aug 3).
   Google Scholar
• Appendix B. Glossary. Pharmacoepidemiology, 6th Ed. Hoboken, NJ: Wiley-Blackwell; 2020:1141-1154. http://10.1002/9781119413431.app2
   Google Scholar
• Kobak KA, Taylor LVH, Katzelnick DJ, et al. Antidepressant medication management and health plan employer data information set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry. 2002;63:727–732.
   PubMed Web of Science ®Google Scholar
• Jacobus S, Schneeweiss S, Chan KA. Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf. 2004;13:695–702.
   PubMed Web of Science ®Google Scholar
• Li X, Stürmer T, Alan Brookhart M. Evidence of sample use among new users of statins: implications for pharmacoepidemiology. Med Care. 2014;52:773–780.
   PubMed Web of Science ®Google Scholar
• Merola J, Chen N, Sundaram M, et al. Medication utilization patterns of apremilast among patients with psoriatic arthritis. J Manag Care Spec Pharm. 2016;22:S101.
   Google Scholar
• Zhang Z, Eworuke E, Goulding M, et al. Misclassification of time-at-risk due to free sample drug use: a simulation study. Pharmacoepidemiol Drug Saf. 2018;27:66–67.
   Web of Science ®Google Scholar
• Ray WA, Stein CM, Daugherty JR, et al. 2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071–1073.
   PubMed Web of Science ®Google Scholar
• Amgen to acquire otezla for $13.4 billion in cash or approximately $11.2 billion net of anticipated future cash tax benefits. Amgen I n.d. http://www.amgen.com/en/media/news-releases/2019/08/amgen-to-acquire-otezla-for-134-billion-in-cash-or-approximately-112-billion-net-of-anticipated-future-cash-tax-benefits (2020 Aug 4).
   Google Scholar
• Boomer E, Hofverberg E, Umeda S, et al. Supply Chain Regulation of Pharmaceutical Samples. The Law Library of Congress, Global Legal Research Directorate. 2019:1-24.. LL File No. 2019-018221.
   Google Scholar
• Tyupa V, Shadrin A. Distribution and marketing of drugs in the Russian Federation: overview. Thomson Reuters Practical Law n.d. http://uk.practicallaw.thomsonreuters.com/5-618-5113?contextData=(sc.Default)&transitionType=Default&firstPage=true (2020Dec 27).
   Google Scholar
• Gokhale M, Girman C, Chen Y, et al. Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2016;25:512–520.
   PubMed Web of Science ®Google Scholar
• Bailey RA, Schwab P, Xu Y, et al. Glycemic control outcomes after canagliflozin initiation: observations in a medicare and commercial managed care population in clinical practice. Clin Ther. 2016;38(2046–2057):e2.
   PubMed Web of Science ®Google Scholar
• Young JC, Stürmer T, Lund JL, et al. Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data. Pharmacoepidemiol Drug Saf. 2016;25:836–843.
   PubMed Web of Science ®Google Scholar
• Franklin JM, Schneeweiss S, Polinski JM, et al. Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. Comput Stat Data Anal. 2014;72:219–226.
   PubMed Web of Science ®Google Scholar
• Parker L, Williams J, Bero L. Ethical drug marketing criteria for the 21st century. BMJ. 2018;361.
   PubMed Web of Science ®Google Scholar
• Lussier M-T, Diallo FB, Pluye P, et al. Drug samples in family medicine teaching units: a cross-sectional descriptive study: part 3: availability and use of drug samples in Quebec. Can Family Physician. 2018;64:e546–52.
   PubMed Web of Science ®Google Scholar
• Gagne JJ. Restrictive reimbursement policies: bias implications for claims-based drug safety studies. Drug Saf. 2014;37:771–776.
   PubMed Web of Science ®Google Scholar